Europe Hypodermics Market Size, Share & Trends Analysis Report By Product (Hypodermic Needles, Hypodermic Syringes), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 1 Business Day
Europe Clear Aligners Market Growth & Trends
The Europe clear aligners market size is anticipated to reach USD 6.37 billion by 2030 and is projected to grow at a CAGR of 26.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market are the rising prevalence of malocclusion, rapid technological advancements in dental health, growing demand for customized aligners, and government initiatives. Europe exhibits high rates of malocclusion, led by the prevalence of deep overbite and posterior crossbite. According to an MDPI article published in May 2024, in reviewed studies, Europe has a significant prevalence of various malocclusions, with 61.50% in the region. Regarding specific types of malocclusion, Europe recorded the highest prevalence of deep overbite at 33.08% and posterior crossbite at 15.38%. Statistically significant differences were found in anterior open bite, deep overbite, edge-to-edge incisor relationship, posterior crossbite, and distal step among the continents, with Europe leading in the prevalence of certain conditions.
Advancements in dental health technology in Europe are transforming the global market. According to a Dentistry UK article published in February 2024, shape memory polymers, based on a concept developed in NASA’s labs, now enable clear aligners to achieve effective teeth alignment with fewer adjustments, significantly reducing treatment time and costs. This innovation enhances patient satisfaction and allows dental professionals to streamline their practices and treat more patients efficiently.
These technological developments emphasize personalized care, tailoring treatment plans to individual patient needs while optimizing operational efficiency. Companies like ClearX are in charge of eco-friendly aligners that minimize plastic waste by utilizing advanced shape-shifting technology and incorporating heat boosters for precise treatment. Moreover, integrating 3D printing technology has revolutionized treatment planning accuracy, offering new opportunities to lower costs and improve treatment outcomes by minimizing the need for corrective adjustments. These advancements highlight Europe's leadership in innovative dental health solutions, promising a future of more accessible, efficient, and sustainable orthodontic care.
Europe Clear Aligners Market Report Highlights
Europe Clear Aligners Market Growth & Trends
The Europe clear aligners market size is anticipated to reach USD 6.37 billion by 2030 and is projected to grow at a CAGR of 26.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market are the rising prevalence of malocclusion, rapid technological advancements in dental health, growing demand for customized aligners, and government initiatives. Europe exhibits high rates of malocclusion, led by the prevalence of deep overbite and posterior crossbite. According to an MDPI article published in May 2024, in reviewed studies, Europe has a significant prevalence of various malocclusions, with 61.50% in the region. Regarding specific types of malocclusion, Europe recorded the highest prevalence of deep overbite at 33.08% and posterior crossbite at 15.38%. Statistically significant differences were found in anterior open bite, deep overbite, edge-to-edge incisor relationship, posterior crossbite, and distal step among the continents, with Europe leading in the prevalence of certain conditions.
Advancements in dental health technology in Europe are transforming the global market. According to a Dentistry UK article published in February 2024, shape memory polymers, based on a concept developed in NASA’s labs, now enable clear aligners to achieve effective teeth alignment with fewer adjustments, significantly reducing treatment time and costs. This innovation enhances patient satisfaction and allows dental professionals to streamline their practices and treat more patients efficiently.
These technological developments emphasize personalized care, tailoring treatment plans to individual patient needs while optimizing operational efficiency. Companies like ClearX are in charge of eco-friendly aligners that minimize plastic waste by utilizing advanced shape-shifting technology and incorporating heat boosters for precise treatment. Moreover, integrating 3D printing technology has revolutionized treatment planning accuracy, offering new opportunities to lower costs and improve treatment outcomes by minimizing the need for corrective adjustments. These advancements highlight Europe's leadership in innovative dental health solutions, promising a future of more accessible, efficient, and sustainable orthodontic care.
Europe Clear Aligners Market Report Highlights
- Based on age group, the adult segment led the market with the largest revenue share of 62.2% in 2023. The adult group includes people over 15 years old. A growing number of adults are opting for orthodontic treatment, subsequently increasing the demand for clear aligners that are more aesthetic and comfortable than traditional appliances like metal braces
- Based on distribution channel, the offline segment led the market with the largest revenue share of 89.3% in 2023; owing to key players’ analysis, a significant portion of the distribution and sales of digitally automated clear aligners are through offline channels
- Based on sales channel, the business to business (B2B) segment led the market with the largest revenue share of 83.2% in 2023. The B2B channel focuses on transactions between manufacturers, dental laboratories, orthodontists, and dental clinics
- Key countries in the European region are Germany, the UK, Spain, and France. The growing importance of aesthetics and improved self-confidence post-treatment are major factors expected to boost the market
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Type
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources & Third-Party Perspectives
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.2.1. Market Driver Analysis
3.2.1.1. Increase in number of needlestick injuries
3.2.1.2. Rising vaccination rates and campaigns
3.2.1.3. Advancements in hypodermic syringes and needles
3.2.2. Market Restraint Analysis
3.2.2.1. Product recalls and field safety notices
3.2.2.2. Adverse effects associated with hypodermic needles
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
CHAPTER 4. PRODUCT TYPE BUSINESS ANALYSIS
4.1. Product Segment Dashboard
4.2. Europe Hypodermic Syringes and Needles Market: Product Type Movement Analysis
4.3. Europe Hypodermic Syringes and Needles Market Size & Trend Analysis, by Product Type, 2018 - 2030 (USD Million)
4.4. Hypodermic Syringes
4.4.1. Hypodermic Syringes Market, 2018 - 2030 (USD Million)
4.4.2. Conventional Syringes
4.4.2.1. Conventional Syringes Market, 2018 - 2030 (USD Million)
4.4.3. Safety Syringes
4.4.3.1. Safety Syringes Market, 2018 - 2030 (USD Million)
4.4.3.2. Retractable Safety Syringes
4.4.3.2.1. Retractable Safety Syringes Market, 2018 - 2030 (USD Million)
4.4.3.3. Non-retractable Safety Syringes
4.4.3.3.1. Retractable Safety Syringes Market, 2018 - 2030 (USD Million)
4.5. Hypodermic Needles
4.5.1. Hypodermic Needles Market, 2018 - 2030 (USD Million)
4.5.2. Conventional Needles
4.5.2.1. Conventional Needles Market, 2018 - 2030 (USD Million)
4.5.3. Safety Needles
4.5.3.1. Safety Needles Market, 2018 - 2030 (USD Million)
CHAPTER 5. END USE BUSINESS ANALYSIS
5.1. End Use Segment Dashboard
5.2. Europe Hypodermic Syringes and Needles Market: End-use Movement Analysis
5.3. Europe Hypodermic Syringes and Needles Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
5.5. Clinics
5.5.1. Clinics Market, 2018 - 2030 (USD Million)
5.6. Ambulatory Surgical Centers
5.6.1. Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
5.7. Veterinary
5.7.1. Veterinary Market, 2018 - 2030 (USD Million)
5.8. Home Care
5.8.1. Home Care Market, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. EUROPE HYPODERMIC SYRINGES AND NEEDLES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY PRODUCT TYPE, END USE
6.1. Regional Dashboard
6.2. Market Size and Trend Analysis, 2018 to 2030
6.3. Europe
6.3.1. Europe hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.2. U.K.
6.3.2.1. Key country dynamics
6.3.2.2. Competitive scenario
6.3.2.3. Regulatory framework
6.3.2.4. Reimbursement scenario
6.3.2.5. U.K. hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.3. Ireland
6.3.3.1. Key country dynamics
6.3.3.2. Competitive scenario
6.3.3.3. Regulatory framework
6.3.3.4. Reimbursement scenario
6.3.3.5. Ireland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.4. Denmark
6.3.4.1. Key country dynamics
6.3.4.2. Competitive scenario
6.3.4.3. Regulatory framework
6.3.4.4. Reimbursement scenario
6.3.4.5. Denmark hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.5. Finland
6.3.5.1. Key country dynamics
6.3.5.2. Competitive scenario
6.3.5.3. Regulatory framework
6.3.5.4. Reimbursement scenario
6.3.5.5. Finland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.6. Iceland
6.3.6.1. Key country dynamics
6.3.6.2. Competitive scenario
6.3.6.3. Regulatory framework
6.3.6.4. Reimbursement scenario
6.3.6.5. Iceland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.7. Norway
6.3.7.1. Key country dynamics
6.3.7.2. Competitive scenario
6.3.7.3. Regulatory framework
6.3.7.4. Reimbursement scenario
6.3.7.5. Norway hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key country dynamics
6.3.8.2. Competitive scenario
6.3.8.3. Regulatory framework
6.3.8.4. Reimbursement scenario
6.3.8.5. Sweden hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Company Market Position Analysis
7.3. Strategy Mapping
7.4. Company Profiles/Listing
7.4.1. BD (Becton, Dickinson & Corporation)
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Cardinal Health
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. B. Braun SE
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. ICU Medical
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Terumo Corporation
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Nipro Europe Group Companies (Nipro Corporation)
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. SolM
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. GBUK Group Ltd.
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Type
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources & Third-Party Perspectives
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.2.1. Market Driver Analysis
3.2.1.1. Increase in number of needlestick injuries
3.2.1.2. Rising vaccination rates and campaigns
3.2.1.3. Advancements in hypodermic syringes and needles
3.2.2. Market Restraint Analysis
3.2.2.1. Product recalls and field safety notices
3.2.2.2. Adverse effects associated with hypodermic needles
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
CHAPTER 4. PRODUCT TYPE BUSINESS ANALYSIS
4.1. Product Segment Dashboard
4.2. Europe Hypodermic Syringes and Needles Market: Product Type Movement Analysis
4.3. Europe Hypodermic Syringes and Needles Market Size & Trend Analysis, by Product Type, 2018 - 2030 (USD Million)
4.4. Hypodermic Syringes
4.4.1. Hypodermic Syringes Market, 2018 - 2030 (USD Million)
4.4.2. Conventional Syringes
4.4.2.1. Conventional Syringes Market, 2018 - 2030 (USD Million)
4.4.3. Safety Syringes
4.4.3.1. Safety Syringes Market, 2018 - 2030 (USD Million)
4.4.3.2. Retractable Safety Syringes
4.4.3.2.1. Retractable Safety Syringes Market, 2018 - 2030 (USD Million)
4.4.3.3. Non-retractable Safety Syringes
4.4.3.3.1. Retractable Safety Syringes Market, 2018 - 2030 (USD Million)
4.5. Hypodermic Needles
4.5.1. Hypodermic Needles Market, 2018 - 2030 (USD Million)
4.5.2. Conventional Needles
4.5.2.1. Conventional Needles Market, 2018 - 2030 (USD Million)
4.5.3. Safety Needles
4.5.3.1. Safety Needles Market, 2018 - 2030 (USD Million)
CHAPTER 5. END USE BUSINESS ANALYSIS
5.1. End Use Segment Dashboard
5.2. Europe Hypodermic Syringes and Needles Market: End-use Movement Analysis
5.3. Europe Hypodermic Syringes and Needles Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
5.5. Clinics
5.5.1. Clinics Market, 2018 - 2030 (USD Million)
5.6. Ambulatory Surgical Centers
5.6.1. Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
5.7. Veterinary
5.7.1. Veterinary Market, 2018 - 2030 (USD Million)
5.8. Home Care
5.8.1. Home Care Market, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. EUROPE HYPODERMIC SYRINGES AND NEEDLES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY PRODUCT TYPE, END USE
6.1. Regional Dashboard
6.2. Market Size and Trend Analysis, 2018 to 2030
6.3. Europe
6.3.1. Europe hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.2. U.K.
6.3.2.1. Key country dynamics
6.3.2.2. Competitive scenario
6.3.2.3. Regulatory framework
6.3.2.4. Reimbursement scenario
6.3.2.5. U.K. hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.3. Ireland
6.3.3.1. Key country dynamics
6.3.3.2. Competitive scenario
6.3.3.3. Regulatory framework
6.3.3.4. Reimbursement scenario
6.3.3.5. Ireland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.4. Denmark
6.3.4.1. Key country dynamics
6.3.4.2. Competitive scenario
6.3.4.3. Regulatory framework
6.3.4.4. Reimbursement scenario
6.3.4.5. Denmark hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.5. Finland
6.3.5.1. Key country dynamics
6.3.5.2. Competitive scenario
6.3.5.3. Regulatory framework
6.3.5.4. Reimbursement scenario
6.3.5.5. Finland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.6. Iceland
6.3.6.1. Key country dynamics
6.3.6.2. Competitive scenario
6.3.6.3. Regulatory framework
6.3.6.4. Reimbursement scenario
6.3.6.5. Iceland hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.7. Norway
6.3.7.1. Key country dynamics
6.3.7.2. Competitive scenario
6.3.7.3. Regulatory framework
6.3.7.4. Reimbursement scenario
6.3.7.5. Norway hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key country dynamics
6.3.8.2. Competitive scenario
6.3.8.3. Regulatory framework
6.3.8.4. Reimbursement scenario
6.3.8.5. Sweden hypodermic syringes and needles market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Company Market Position Analysis
7.3. Strategy Mapping
7.4. Company Profiles/Listing
7.4.1. BD (Becton, Dickinson & Corporation)
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Cardinal Health
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. B. Braun SE
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. ICU Medical
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Terumo Corporation
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Nipro Europe Group Companies (Nipro Corporation)
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. SolM
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. GBUK Group Ltd.
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives